Actelion's $250M deal for Ceptaris moves ahead; Ranbaxy may abandon smaller global markets;

@FiercePharma: Japan's budget-minded PM wants to open universal health system to more add-on treatments. Could boost cancer meds. Article | Follow @FiercePharma

@EricPFierce: Australia to track Yervoy patients to see if it's worth the $110K price. More | Follow @EricPFierce

@CarlyHFierce: Ex-Novartis chair Vasella considers his results worth the once-approved $78M payout--will make $5.2M instead. Story | Follow @CarlyHFierce

> Swiss-based Actelion ($ATLN) said its acquisition target Ceptaris won approval for its Valchlor gel drug in the U.S., clearing the way to wrap up the $250 million deal. Report

> India's Ranbaxy Laboratories may pull out of small markets around the world to focus on becoming a leader in selected key countries. Report

> Horizon Pharma and Par Pharmaceutical settled their patent fight over Duexis, which combines ibuprofen with the antacid drug Pepcid. Report

> Japan's Astellas Pharma launched a once-daily oral version of Astragraf, used to prevent organ rejection in kidney transplant patients. Report

> Indian antitrust officials will review 6 proposed pharma deals Tuesday amid calls for tighter restrictions on foreign investment in the sector. Report

> India's Lupin won FDA approval for its version of Sanofi's ($SNY) Rifampin, known generically as rifadin, a treatment for tuberculosis. Report

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter this Wednesday. Sign up | Follow @FierceMedDev

@DamianFierce: CROs are dishing out more and more bonuses to quell sky-high turnover rates, according to a study. Report | Follow @DamianFierce

@MarkHFierce: Thermo Fisher is rolling out a major scholarship program for science/math students at elite universities. Smart. Release | Follow @MarkHFierce

@MichaelGFierce: Zimmer lands FDA clearance for 3-D surgical system. Article | Follow @MichaelGFierce

> Medtronic fails to stop patient's Infuse lawsuit. News

> Investment bank launches healthcare-focused crowdfunding option. Item

Biotech News

@FierceBiotech: Rigel shares slide after another drug flops in PhII asthma study. Story | Follow @FierceBiotech

@JohnCFierce: Two years ago Rigel was celebrating when Pfizer turned over R343. Now enthusiasm likely dimmed as top 2 drugs are under a dark cloud. | Follow @JohnCFierce

@EmilyMFierce: High copper levels implicated in #Alzheimer's disease. Story | Follow @EmilyMFierce

> Argos turns to unusual players for $42.5M needed to fund PhIII cancer study. News

> AstraZeneca forges $500M cancer-combo tech buyout for MedImmune. More

> Amgen bags Onyx Pharma in $10.4B buyout deal. Story

CRO News

> U.K. outfit bets on early-phase outsourcing. News

> CRO Psi jumps into India. More

> Vince & Associates eyes gastro trials with expansion. Article

> Study: CROs dishing out bonuses to halt high turnover. Story

> Icon dives into adaptive trial monitoring. News

Biotech IT News

> Capgemini taps Amazon cloud for Big Data analytics. Story

> Harvard-MIT collaboration adds Lego-like genome analysis tool. Article

> Google bolsters security of cloud data storage service. More

> FDA pilot project ups benefits of IT supply chain investments. News

> EMA to start accepting digital signatures next month. Story

And Finally... The American Academy of Pediatrics said breast-feeding mothers can take most prescription drugs without a risk to their babies' health. Report

Suggested Articles

Belgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world. That was the goal of an Ind

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.